Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK.  Impact of early statin use on outcomes after coronary artery bypass graft surgery. Circulation 2008;118:1785-92.

Kulik A, Le May MR, Voisine P, Tardif JC, DeLarochelliere R, Naidoo S, Wells GA, Mesana TG, Ruel M.  Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the CASCADE trial.  Circulation 2010;122:2680-7.

Kulik A, Desai NR, Shrank WH, Antman EM, Glynn RJ, Levin R, Choudhry NK.  Full prescription coverage versus usual prescription coverage after coronary artery bypass graft surgery for recent myocardial infarction: analysis from the MI FREEE randomized trial.  Circulation 2013;128:S219-225.

Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, Lopez-Jimenez F, McNallan SM, Patel M, Roger VL, Sellke FW, Sica DA, Zimmerman L.  Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association.  Circulation 2015:131:927-64.

Greenstein D, Beau J, Gottlieb G, Teller D, Kulik A.  Topical amiodarone during cardiac surgery: does epicardial application of amiodarone prevent postoperative atrial fibrillation?  J Thorac Cardiovasc Surg 2017;154:886-92.

Kulik A, Abreu AM, Boronat V, Ruel, M.  Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG: rationale and design of the ACTIVE (aggressive cholesterol therapy to inhibit vein graft events) randomized controlled trial (NCT01528709).  Contemp Clin Trials 2017;59:98-104.

Kulik A, Abreu AM, Boronat V, Kouchoukos NT, Ruel, M.  Impact of ticagrelor versus aspirin on graft patency after CABG: rationale and design of the TARGET (ticagrelor antiplatelet therapy to reduce graft events and thrombosis) randomized controlled trial (NCT02053909).